verapamil and Arrhythmia studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Research Excerpts

Excerpt	Relevance	Reference
"The effect of verapamil on death and reinfarction after an acute myocardial infarction was studied in two double-blind, randomized, placebo-controlled multicenter trials, the Danish Verapamil Infarction Trials I and II (DAVIT I and II)."	10.16	Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. ( Hansen, JF, 1991)
"Evaluation of efficacy of intravenous flecainide to revert supraventricular arrhythmias to sinus rhythm in patients with respiratory insufficiency."	9.07	Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. ( Barranco, F; Guerrero, M; Rodriguez, J; Sanchez, M, 1994)
"This article is a review of presented subsets of the Danish Verapamil Infarction Trial II (DAVIT II) regarding the effect of verapamil on postinfarction ischemia, ventricular arrhythmias, and heart rate (HR), and the prognostic implications of these findings."	9.07	Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Holländer, NH; Mellemgaard, K; Nielsen, I; Rasmussen, V; Sigurd, B; Sørensen, MB; Vaage-Nilsen, M, 1991)
"The antiarrhythmic efficacy of intravenous flecainide and intravenous digoxin was assessed in 29 patients (26 men), aged 43 to 73 (63 +/- 7) years who developed atrial arrhythmias in the first 96 hours after coronary artery bypass grafting."	9.06	Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. ( Camm, AJ; Parker, DJ; Wafa, SS; Ward, DE, 1989)
"Although the antiarrhythmic effects of verapamil (V) have been studied widely, its role in the treatment of atrial tachyarrhythmias after open-heart surgery (OHS) has not been defined."	9.05	Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery. ( Conklin, CM; Gray, RJ; Mandel, WJ; Matloff, JM; Sethna, DH, 1982)
"This study investigated the efficacy of oral administration of verapamil, started 24 hours after coronary artery bypass grafting (CABG), in reducing the incidence of postoperative supraventricular tachyarrhythmia (SVT)."	9.05	Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. ( Davison, R; Feiereisel, P; Hartz, R; Kaplan, K; Michaelis, L; Parker, M, 1985)
"A double-blind randomized study was performed to compare the efficacy of intravenous verapamil with saline in 28 patients with a rapid ventricular rate and atrial fibrillation or atrial flutter."	9.04	Verapamil in atrial fibrillation and atrial flutter. ( Aronow, WS; Ferlinz, J; Karlsberg, RP; Landa, D; Plasencia, G; Wong, R, 1979)
" Verapamil remains the most widely used calcium antagonist for the treatment of cardiac arrhythmias."	8.76	Verapamil in cardiac arrhythmias: an overview. ( Vohra, J, 1982)
"It is clear from clinical and experimental data that have been reported thus far that verapamil is highly effective in the therapy of cardiac arrhythmias, and that it acts by a different mechanism than most of the commonly used antiarrhythmic drugs."	8.75	Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. ( Hoffman, BF; Rosen, MR; Wit, AL, 1975)
"We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)."	8.31	Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023)
"Simvastatin (SV) leads to reduction of ventricular rhythm during atrial fibrillation on rabbit atrioventricular (AV) nodes."	7.81	Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit. ( Alizadeh, AM; Aminolsharieh Najafi, S; Khori, V; Moheimani, HR; Nayebpour, M; Shakiba, D; Zahedi, M, 2015)
"To study the anti-arrhythmic efficacy of ginsenoside Re (GSRe) and its protective effects against myocardial injuries in rabbits with isoproterenol-induced triggered ventricular arrhythmia (TVA)."	7.75	[Protective effect of ginsenoside Re on isoproterenol-induced triggered ventricular arrhythmia in rabbits]. ( Chen, CX; Zhang, HY, 2009)
"Aim of this study was to investigate antiarrhythmic and toxic effects of verapamil in mice and rats with thyrotoxicosis and hypothyroidism."	7.74	[Characteristics of pharmacological and toxic effects of verapamil during cardiac arrhythmia in thyrotoxic and hypothyroid rats]. ( Afanas'eva, EIu; Arzamastsev, EV; Sokhanenkov, MIu; Sokhanenkova, AE, 2008)
") administration of (+/-) propranolol (100-200-300 microg/animal/day, during 7 days) or (+/-) verapamil (40-80-160 microg/animal/day, during 7 days) afforded a significant protection (with the exception of the lowest dose) on the investigated parameters: arrhythmias, ischemic zone (in coronary ligated rats), lactate dehydrogenase and aspartate aminotransferase activity of the serum, focal necrosis (in isoproterenol treated rats)."	7.70	The influence of intracerebroventricular administration of (+/-) propranolol and (+/-) verapamil on experimental myocardial ischemia and necrosis in rats. ( Blidaru, M; Cuparencu, B; Pleşca-Manea, L, 2000)
"Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs."	7.69	Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995)
"The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model."	7.69	Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995)
"The effects of the specific bradycardic agent, zatebradine (UL-FS 49), on ventricular arrhythmias occurring during an acute ischemia were compared to those of verapamil."	7.69	Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits. ( Bril, A; Cheval, B; Forest, MC; Gout, B; Landais, L, 1994)
"Because the relative efficacy of antiarrhythmic agents on halothane-epinephrine arrhythmias has not been well characterized, this study was undertaken to comparatively evaluate the antiarrhythmic action of Na(+)-, K(+)- and Ca(2+)-channel blockers on epinephrine-induced ventricular arrhythmias during halothane anesthesia in rats."	7.68	Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats. ( Hayashi, Y; Kamibayashi, T; Kawabata, K; Sumikawa, K; Takada, K; Yamatodani, A; Yoshiya, I, 1993)
"Several studies have suggested a central role for Na+/Ca2+ in the pathogenesis of ouabain-induced cardiac arrhythmias."	7.68	Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. ( De Clerck, F; Lu, HR; Remeysen, P, 1993)
"To clarify mechanisms underlying an enhanced susceptibility to cardiac rhythm disturbances in hypertension and myocardial hypertrophy, we evaluated the vulnerability to histamine-induced arrhythmias of isolated left ventricles from spontaneously hypertensive rats (SHR) and age-matched controls (Wistar-Kyoto rats, WKY)."	7.68	Enhanced susceptibility to histamine-induced cardiac arrhythmias in spontaneously hypertensive rats. ( Bassett, AL; Cameron, JS; Katz, D; Shin, GS; Swigart, CR, 1990)
"The effects of verapamil and nifedipine on cellular mechanisms of arrhythmia were examined in isolated canine Purkinje fiber-papillary muscles."	7.68	Effects of verapamil and nifedipine on mechanisms of arrhythmia in an in vitro model of ischemia and reperfusion. ( Ferrier, GR; Mohabir, R, 1991)
"A patient with pre-existing peripheral neuropathy developed generalized fasciculations under verapamil which ceased after discontinuation of the drug."	7.68	Fasciculations due to verapamil in a patient with neuropathy. ( Hopf, HC; Röder, R; Thömke, F; Vogt, T, 1990)
"The actions of intravenous verapamil against arrhythmias induced by occlusion of a coronary artery were investigated in conscious rats."	7.67	Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. ( Curtis, MJ; MacLeod, BA; Walker, MJ, 1984)
"The antiarrhythmic activity of the calcium entry blockers, verapamil, nifedipine and prenylamine, was assessed against arrhythmias occurring during 20 min of acute occlusion, or upon rapid reperfusion of the left anterior descending coronary artery (LAD) in anesthetized pigs."	7.67	Acute coronary artery occlusion-reperfusion arrhythmias in pigs: antiarrhythmic and antifibrillatory evaluation of verapamil, nifedipine, prenylamine and propranolol. ( Bergey, JL; McCallum, JD; Nocella, K; Wendt, RL, 1984)
"Recently, this laboratory has demonstrated an enhanced susceptibility toward the development of lethal ventricular arrhythmias occurring in response to acute posterolateral ischemia in dogs with previous anterior myocardial infarction in the presence of therapeutic serum concentrations of digoxin."	7.67	Effect of digoxin on the extent of injury and the severity of arrhythmias during acute myocardial ischemia and infarction in the dog. ( Lucchesi, BR; Lynch, JJ, 1988)
"The antiarrhythmic effect of verapamil was tested on spontaneous ventricular arrhythmias during reoxygenation after 15 min of glucose-free hypoxia and on programmed electrical stimulation-(8 stimuli + 1 or 2 extrastimuli) induced ventricular fibrillation in isolated Langendorff perfused guinea pig hearts."	7.67	Effects of verapamil on reoxygenation and programmed electrical stimulation-induced ventricular arrhythmias in the isolated heart. ( Bernabei, R; Carbonin, PU; Gambassi, G; Pahor, M, 1989)
" We report a patient with atrial flutter-fibrillation who developed cyclic sinus node dysfunction with profound ventricular pauses in response to small doses of digoxin, verapamil, and propranolol, which resolved with discontinuation of the medications."	7.67	Hyperthyroid-induced atrial flutter-fibrillation with profound sinoatrial nodal pauses due to small doses of digoxin, verapamil, and propranolol. ( Hurst, JW; Talley, JD; Wathen, MS, 1989)
"There is increasing evidence that the use of cocaine can trigger lethal cardiac events, including ventricular fibrillation."	7.67	Cocaine-induced ventricular fibrillation: protection afforded by the calcium antagonist verapamil. ( Billman, GE; Hoskins, RS, 1988)
"Intravenous picrotoxin injection has been established as a model of producing arrhythmias, mainly through enhanced central sympathetic outflow."	7.67	Effects of calcium-channel blockers on picrotoxin-induced centrogenic arrhythmias in cats. ( Chai, CY; Chiang, BN; Deng, JF; Hou, ZY; Kuo, JS; Liu, RH, 1988)
"Protective influence of verapamil upon ouabain-induced cardiac arrhythmias was investigated in anesthetized (alpha-chloralose 60 mg/kg and urethane 500 mg/kg) open-chest guinea pigs."	7.67	Protective effect of verapamil upon ouabain-induced cardiac arrhythmias. ( Hoeschen, RJ; Khatter, JC; Navaratnam, S, 1988)
"In this study prophylactic antiarrhythmic effects of verapamil on exercise-induced ventricular arrhythmias are evaluated."	7.67	Prophylaxis of exercise-induced ventricular arrhythmias by verapamil. ( Behrenbeck, T; Bender, F; Godejohann, U; Gülker, H; Heuer, H, 1987)
"In this study prophylactic antiarrhythmic effects of verapamil on exercise-induced ventricular arrhythmias were evaluated in a total of 22 patients."	7.67	[Prevention of effort-induced ventricular arrhythmia using verapamil]. ( Behrenbeck, T; Bender, F; Dorsel, T; Godejohann, U; Gülker, H; Heuer, H, 1987)
"This study was designed to clarify the mechanism of reperfusion arrhythmia and with the effect of verapamil on arrhythmia."	7.67	The effect of verapamil on reperfusion arrhythmia in canine heart. ( Hattori, M; Miyazaki, Y; Nagai, S; Ozawa, T; Sugiyama, S, 1985)
"The effects of verapamil and bepridil on occlusion and reperfusion ventricular arrhythmias including ventricular fibrillation (VF) were studied in a canine model."	7.67	Effects of verapamil and bepridil on occlusion and reperfusion arrhythmias in the canine heart. ( Belhassen, B; Chagnac, A; Laniado, S; Pardo, Y; Pelleg, A; Shargordsky, B, 1985)
"Verapamil, a calcium channel blocking drug, terminates supraventricular arrhythmias but may have a negative inotropic effect and produce peripheral vasodilatation and hypotension."	7.66	The use of calcium with verapamil in the management of supraventricular tachyarrhythmias. ( Gotsman, MS; Halon, DA; Hasin, Y; Lewis, BS; Weiss, AT, 1983)
"Certain general conclusions suggest themselves on the basis of our extensive experience with treating arrhythmias in patients following open heart surgery, our specific results with verapamil therapy in the treatment of atrial fibrillation and atrial flutter in patients following open heart surgery, and the results of verapamil therapy administered in other groups of patients."	7.66	Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery. ( Arciniegas, JG; Henthorn, RW; Plumb, VJ; Waldo, AL; Zimmern, SH, 1983)
" It did not antagonize the deslanoside arrhythmias, but inhibited transiently the arrhythmias induced by either electrical stimulation of the posterior hypothalamus or bilateral carotid occlusion in cats."	7.65	Effect of verapamil on experimental arrhythmias. ( Huang, TF; Peng, YI, 1977)
"In 12 patients affected by acute myocardial infarction complicated only by ventricular extrasystoles, verapamil was highly effective in the control of the arrhythmias."	7.65	[The antiarrhythmic effects of verapamil in acute myocardial infarction. Considerations on the possible action mechanism (author's transl)]. ( Fazzini, PF; Marchi, F; Pucci, P, 1977)
"Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type."	7.65	[Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias]. ( Amoroso, A, 1975)
"The effects of intravenous verapamil on the electrocardiogram in 15 patients with heart disease in sinus rhythm and in 44 patients with supraventricular and ventricular tachyarrhythmias were evaluated."	7.65	Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. ( Heng, MK; Mercer, CJ; Norris, RM; Roche, AH; Singh, BN, 1975)
"Verapamil was administered by intravenous injection to 181 patients with various cardiac arrhythmias."	7.65	Immediate effects of intravenous verapamil in cardiac arrhythmias. ( Garrett, C; Krikler, DM; Schamroth, L, 1972)
"In the verapamil group ventricular arrhythmias increased from 25 to 33% (NS)."	6.67	Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM; Vaage-Nilsen, M, 1993)
"Verapamil caused a lower ventricular rate, but only six (19%) of the patients (n = 31) converted to sinus rhythm within 4 h (p < 0."	6.67	The effect of magnesium versus verapamil on supraventricular arrhythmias. ( Birkeland, K; Gullestad, L; Høyer, MM; Kjekshus, J; Mølstad, P; Vanberg, P, 1993)
"The effect of verapamil on death and reinfarction after an acute myocardial infarction was studied in two double-blind, randomized, placebo-controlled multicenter trials, the Danish Verapamil Infarction Trials I and II (DAVIT I and II)."	6.16	Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. ( Hansen, JF, 1991)
"Thus verapamil was more efficacious than anipamil at providing antiarrhythmic protection against both early and late onset arrhythmias."	5.29	Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. ( Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995)
"Mibefradil is a new calcium antagonist that can inhibit cardiac calcium current without reducing myocardial force development."	5.29	The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. ( Billman, GE; Hamlin, RL, 1996)
"Arrhythmias were associated with prolongation of transmural conduction time (CT) and abbreviation of endocardial effective refractory period."	5.28	Verapamil prevents slowing of transmural conduction and suppresses arrhythmias in an isolated guinea pig ventricular model of ischemia and reperfusion. ( Ferrier, GR; Li, GR, 1992)
"To test the hypothesis that such arrhythmias may be mediated by sarcolemmal stretch-activated channels, we attempted to inhibit stretch-induced arrhythmias with gadolinium (Gd3+), a potent stretch-activated channel blocker."	5.28	Dose-dependent inhibition of stretch-induced arrhythmias by gadolinium in isolated canine ventricles. Evidence for a unique mode of antiarrhythmic action. ( Borganelli, M; Hansen, DE; Stacy, GP; Taylor, LK, 1991)
"This arrhythmia, similar to the more common uniform AIVR, was intermittent, did not cause hemodynamic compromise, and was not related to more serious ventricular arrhythmias."	5.27	Multiform accelerated idioventricular rhythm in acute myocardial infarction: electrocardiographic characteristics and response to verapamil. ( Agmon, J; Arditi, A; Fuchs, J; Klainman, E; Kracoff, OH; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983)
"Models of ischemic and reperfusion arrhythmias were reproduced in isolated rat hearts by means of the ligation and subsequent reocclusion of the left descending coronary artery."	5.27	[Prevention of ischemic and reperfusion arrhythmias using the calmodulin blocker trifluoperazine]. ( Karpov, RS; Larionov, NP; Malyshev, IIu; Meerson, FZ, 1988)
"The arrhythmias were prevented by higher doses of the calcium antagonist verapamil which, however, decreased the survival times."	5.26	Comparative investigation of the effects of metoprolol, propranolol, practolol, and verapamil in the acute phase of experimental myocardial infarction. ( Bernauer, W, 1982)
"Reentrant ventricular arrhythmias (RVA) were analyzed in dogs 3--7 days after ligation of the anterior descending coronary artery using averaged "composite" recordings of electrical activity of reentrant pathways (RP) from the epicardial surface of the infarction zone (IZ)."	5.26	Reentrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D-600 and the role of the "slow channel". ( El-Sherif, N; Lazzara, R, 1979)
" To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months."	5.09	Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001)
"The Danish Verapamil Infarction Trial II (DAVIT II) demonstrated from the second postinfarction week, that long term treatment with verapamil significantly improved reinfarction free survival after an acute myocardial infarction (AMI)."	5.08	Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. The Danish Verapamil Infarction Trial II (DAVIT II). ( Hagerup, L; Hansen, JF; Mellemgaard, K; Sigurd, B; Steinmetz, E; Vaage-Nilsen, M, 1995)
"Evaluation of efficacy of intravenous flecainide to revert supraventricular arrhythmias to sinus rhythm in patients with respiratory insufficiency."	5.07	Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. ( Barranco, F; Guerrero, M; Rodriguez, J; Sanchez, M, 1994)
"This article is a review of presented subsets of the Danish Verapamil Infarction Trial II (DAVIT II) regarding the effect of verapamil on postinfarction ischemia, ventricular arrhythmias, and heart rate (HR), and the prognostic implications of these findings."	5.07	Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Holländer, NH; Mellemgaard, K; Nielsen, I; Rasmussen, V; Sigurd, B; Sørensen, MB; Vaage-Nilsen, M, 1991)
"The antiarrhythmic efficacy of intravenous flecainide and intravenous digoxin was assessed in 29 patients (26 men), aged 43 to 73 (63 +/- 7) years who developed atrial arrhythmias in the first 96 hours after coronary artery bypass grafting."	5.06	Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. ( Camm, AJ; Parker, DJ; Wafa, SS; Ward, DE, 1989)
"A randomized, double-blinded study was conducted to evaluate the effectiveness of the calcium antagonist verapamil in patients in cardiopulmonary arrest with asystole or pulseless idioventricular rhythm (PIVR)."	5.05	Verapamil in the treatment of asystolic and pulseless idioventricular rhythm cardiopulmonary arrests: a preliminary report. ( Emerman, CL; Martin, GB; Nowak, RM; Tomlanovich, MC, 1984)
"Although the antiarrhythmic effects of verapamil (V) have been studied widely, its role in the treatment of atrial tachyarrhythmias after open-heart surgery (OHS) has not been defined."	5.05	Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery. ( Conklin, CM; Gray, RJ; Mandel, WJ; Matloff, JM; Sethna, DH, 1982)
"This study investigated the efficacy of oral administration of verapamil, started 24 hours after coronary artery bypass grafting (CABG), in reducing the incidence of postoperative supraventricular tachyarrhythmia (SVT)."	5.05	Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. ( Davison, R; Feiereisel, P; Hartz, R; Kaplan, K; Michaelis, L; Parker, M, 1985)
"A double-blind randomized study was performed to compare the efficacy of intravenous verapamil with saline in 28 patients with a rapid ventricular rate and atrial fibrillation or atrial flutter."	5.04	Verapamil in atrial fibrillation and atrial flutter. ( Aronow, WS; Ferlinz, J; Karlsberg, RP; Landa, D; Plasencia, G; Wong, R, 1979)
"This meta-analysis was performed to determine the efficacy of digoxin, verapamil, and beta-adrenoceptor blockers as prophylaxis against supraventricular arrhythmias (SVAs) after coronary artery bypass graft surgery (CABG)."	4.78	Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. ( Andrews, TC; Antman, EM; Berlin, JA; Reimold, SC, 1991)
" In experimental animals, verapamil has been shown to reduce vulnerability to ventricular fibrillation during sympathetic stimulation and to prevent spontaneous fibrillation during both myocardial ischaemia and reperfusion."	4.77	Mechanisms involved in reperfusion arrhythmias. ( Hagestad, EL; Verrier, RL, 1986)
" Verapamil remains the most widely used calcium antagonist for the treatment of cardiac arrhythmias."	4.76	Verapamil in cardiac arrhythmias: an overview. ( Vohra, J, 1982)
"It is clear from clinical and experimental data that have been reported thus far that verapamil is highly effective in the therapy of cardiac arrhythmias, and that it acts by a different mechanism than most of the commonly used antiarrhythmic drugs."	4.75	Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. ( Hoffman, BF; Rosen, MR; Wit, AL, 1975)
"We identified that carvedilol, a β-blocker not commonly used in HCM, suppresses contractile function and arrhythmia by inhibiting RyR2 (ryanodine receptor type 2)."	4.31	Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol. ( Ashley, EA; Bernstein, D; Huang, Y; Kawana, M; Kirillova, A; Lane, KV; Parikh, VN; Perez, MV; Pruitt, BL; Seo, K; Wang, Q; Wheeler, MT; Wu, JC; Yadav, S; Yamamoto, Y, 2023)
" The purpose of the article is to evaluate the incidence of UTI in patients with supraventricular arrhythmia after arrhythmia relief with verapamil."	4.12	Comments of the editorial board on the article "The incidence of atrial infarction in patients with supraventricular arrhythmias" (authors: Bocharov A.V., Popov L.V. DOI:10.18087/cardio.2022.3.n1648). ( Editorial, A, 2022)
"Significant AP prolongation (a pro-arrhythmia marker) was seen in response to quinidine and quinine."	4.12	An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms. ( Christini, DJ; Clark, AP; Kalola, D; Krogh-Madsen, T; Wei, S, 2022)
"Simvastatin (SV) leads to reduction of ventricular rhythm during atrial fibrillation on rabbit atrioventricular (AV) nodes."	3.81	Acute effects of simvastatin to terminate fast reentrant tachycardia through increasing wavelength of atrioventricular nodal reentrant tachycardia circuit. ( Alizadeh, AM; Aminolsharieh Najafi, S; Khori, V; Moheimani, HR; Nayebpour, M; Shakiba, D; Zahedi, M, 2015)
"This study is to investigate the effects of phenytoin sodium, lidocaine (sodium channel blockers), propranolol (beta-adrenergic receptor antagonist), amiodarone (drugs prolonging the action potential duration) and verapamil (calcium channel blockers) on arrhythmia of mice induced by Bufonis Venenum (Chansu) and isolated mouse hearts lethal dose of Chansu."	3.77	[Effect of anti-arrhythmia drugs on mouse arrhythmia induced by Bufonis Venenum]. ( Ding, AW; Duan, JA; Lü, GH; Lu, WJ; Ma, HY; You, FQ; Zhou, J, 2011)
" The antiarrhythmic action of one furofuran lignan, liriodendrin (2), was tested on a model of CaCl(2)-induced arrhythmia and compared with the effect of verapamil."	3.76	A new triterpene and an antiarrhythmic liriodendrin from Pittosporum brevicalyx. ( Feng, C; Gao, XP; Li, BG; Qi, HY; Zhang, GL, 2010)
"To study the anti-arrhythmic efficacy of ginsenoside Re (GSRe) and its protective effects against myocardial injuries in rabbits with isoproterenol-induced triggered ventricular arrhythmia (TVA)."	3.75	[Protective effect of ginsenoside Re on isoproterenol-induced triggered ventricular arrhythmia in rabbits]. ( Chen, CX; Zhang, HY, 2009)
"Verapamil, which has profound electrophysiologic effects on the slow inward current, is emerging as a valuable antiarrhythmic agent."	3.75	Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. ( Antman, EM; Braunwald, E; Muller, JE; Stone, PH, 1980)
"Aim of this study was to investigate antiarrhythmic and toxic effects of verapamil in mice and rats with thyrotoxicosis and hypothyroidism."	3.74	[Characteristics of pharmacological and toxic effects of verapamil during cardiac arrhythmia in thyrotoxic and hypothyroid rats]. ( Afanas'eva, EIu; Arzamastsev, EV; Sokhanenkov, MIu; Sokhanenkova, AE, 2008)
"We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats."	3.73	Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006)
"To analyze action of digoxin and some non-digitalis drugs (beta-blockers, verapamil, amiodarone, d,l-sotalol) and their combinations on electrical activity of atria, frequency and structure of ventricular rhythm in patients with permanent atrial fibrillation."	3.72	[Correction of rate and structure of ventricular rhythm in permanent atrial fibrillation: a novel pathogenetic approach]. ( Blagova, OV; Bogdanova, EA; Nedostup, AV; Platonova, AA, 2004)
"Halothane more so than isoflurane potentiates an alpha1-adrenoceptor (alpha1-AR)-mediated action of epinephrine that abnormally slows conduction in Purkinje fibers and may facilitate reentrant arrhythmias."	3.70	Multiple agents potentiate alpha1-adrenoceptor-induced conduction depression in canine cardiac purkinje fibers. ( Bosnjak, ZJ; Contney, S; Kulier, AH; Lathrop, DA; Turner, LA; Vodanovic, S, 2000)
") administration of (+/-) propranolol (100-200-300 microg/animal/day, during 7 days) or (+/-) verapamil (40-80-160 microg/animal/day, during 7 days) afforded a significant protection (with the exception of the lowest dose) on the investigated parameters: arrhythmias, ischemic zone (in coronary ligated rats), lactate dehydrogenase and aspartate aminotransferase activity of the serum, focal necrosis (in isoproterenol treated rats)."	3.70	The influence of intracerebroventricular administration of (+/-) propranolol and (+/-) verapamil on experimental myocardial ischemia and necrosis in rats. ( Blidaru, M; Cuparencu, B; Pleşca-Manea, L, 2000)
"Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with those of other antiarrhythmic drugs."	3.69	Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. ( Haruno, A; Hashimoto, K, 1995)
"The purpose of this study was to examine the hypothesis that the calcium channel blocker verapamil modulates catecholamine-induced arrhythmias in brain and to explore potential mechanisms of action."	3.69	Verapamil has antiarrhythmic effects that are mediated in brain through endogenous opioids. ( Rabkin, SW, 1994)
"The mechanisms of digoxin-induced ventricular arrhythmias were studied in vivo using a novel experimental model."	3.69	Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. ( Hurt, CM; Pelleg, A; Xu, J, 1995)
"The effects of the specific bradycardic agent, zatebradine (UL-FS 49), on ventricular arrhythmias occurring during an acute ischemia were compared to those of verapamil."	3.69	Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits. ( Bril, A; Cheval, B; Forest, MC; Gout, B; Landais, L, 1994)
"Because the relative efficacy of antiarrhythmic agents on halothane-epinephrine arrhythmias has not been well characterized, this study was undertaken to comparatively evaluate the antiarrhythmic action of Na(+)-, K(+)- and Ca(2+)-channel blockers on epinephrine-induced ventricular arrhythmias during halothane anesthesia in rats."	3.68	Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats. ( Hayashi, Y; Kamibayashi, T; Kawabata, K; Sumikawa, K; Takada, K; Yamatodani, A; Yoshiya, I, 1993)
"Hypotension, sinus node suppression, and dysrhythmias often occur with calcium channel blocker overdoses, but atrioventricular nodal block occurs more often with verapamil (chi 2 test, P < ."	3.68	A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. ( Borys, D; Ramoska, EA; Spiller, HA; Winter, M, 1993)
"Several studies have suggested a central role for Na+/Ca2+ in the pathogenesis of ouabain-induced cardiac arrhythmias."	3.68	Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. ( De Clerck, F; Lu, HR; Remeysen, P, 1993)
"Cocaine may produce life-threatening cardiac arrhythmias, but it is not clear whether this is an indirect effect of coronary vasoconstriction and ischemia or a direct myocardial effect of the substance."	3.68	Early afterdepolarizations and triggered activity induced by cocaine. A possible mechanism of cocaine arrhythmogenesis. ( Bassett, AL; Kimura, S; Myerburg, RJ; Xi, H, 1992)
"In experiments in white mice and rats the antidepressants pyrazidol (pirlindole), moclobemide and especially tetrindole possess anticalcium activity in tests of calcium chloride-induced lethality in mice and arrhythmia in rats."	3.68	[Anticalcium activity of several antidepressive agents]. ( Andreeva, NI; Golovina, SM; Mashkovskiĭ, MD; Rumiantsev, EA, 1992)
" The action of IHC-72 against aconitine induced arrhythmia was similar to that of Lid but stronger than that of Ver in anesthetized rats."	3.68	[Comparison of antiarrhythmic effects of IHC-72 (an iodonium-72), lidocaine and verapamil]. ( Ji, GJ; Liu, DQ; Sheng, BH; Zhao, DH, 1992)
"To clarify mechanisms underlying an enhanced susceptibility to cardiac rhythm disturbances in hypertension and myocardial hypertrophy, we evaluated the vulnerability to histamine-induced arrhythmias of isolated left ventricles from spontaneously hypertensive rats (SHR) and age-matched controls (Wistar-Kyoto rats, WKY)."	3.68	Enhanced susceptibility to histamine-induced cardiac arrhythmias in spontaneously hypertensive rats. ( Bassett, AL; Cameron, JS; Katz, D; Shin, GS; Swigart, CR, 1990)
"The effects of verapamil and nifedipine on cellular mechanisms of arrhythmia were examined in isolated canine Purkinje fiber-papillary muscles."	3.68	Effects of verapamil and nifedipine on mechanisms of arrhythmia in an in vitro model of ischemia and reperfusion. ( Ferrier, GR; Mohabir, R, 1991)
"A significant potentiation of antiarrhythmic effect was observed in 121 dogs with arrhythmias 24 and 48 hours after the coronary artery ligation when the following drugs were combined: N-propylajmaline bromide (1A class) and trimecaine (1B class), quinidine (1A class) and trimecaine, N-propylajmaline bromide and anaprilin (2 class)."	3.68	[Combined action of anti-arrhythmia agents]. ( Balashov, VP; Gendenshteĭn, EI; Kostin, IaV; Oleĭnikov, VE, 1991)
"A patient with pre-existing peripheral neuropathy developed generalized fasciculations under verapamil which ceased after discontinuation of the drug."	3.68	Fasciculations due to verapamil in a patient with neuropathy. ( Hopf, HC; Röder, R; Thömke, F; Vogt, T, 1990)
"The most common cardiotoxic effects of 5-fluorouracil (5-FU) are chest pain and ischemic ECG abnormalities."	3.68	Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. ( Albertsson, M; Eskilsson, J, 1990)
"The actions of intravenous verapamil against arrhythmias induced by occlusion of a coronary artery were investigated in conscious rats."	3.67	Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. ( Curtis, MJ; MacLeod, BA; Walker, MJ, 1984)
"The ability of the two calcium-antagonists Verapamil and Nifedipine to reduce ventricular electrical instability following acute transient coronary artery occlusion and release and to prevent ventricular arrhythmias, particularly fibrillation, was evaluated on a total of 25 anaesthetized and artificially ventilated dogs."	3.67	[Comparative studies on the anti-arrhythmic and anti-fibrillatory effectiveness of verapamil and nifedipine following acute coronary artery occlusion and reperfusion]. ( Bender, F; Brisse, B; Gülker, H; Thale, J, 1984)
"The antiarrhythmic activity of the calcium entry blockers, verapamil, nifedipine and prenylamine, was assessed against arrhythmias occurring during 20 min of acute occlusion, or upon rapid reperfusion of the left anterior descending coronary artery (LAD) in anesthetized pigs."	3.67	Acute coronary artery occlusion-reperfusion arrhythmias in pigs: antiarrhythmic and antifibrillatory evaluation of verapamil, nifedipine, prenylamine and propranolol. ( Bergey, JL; McCallum, JD; Nocella, K; Wendt, RL, 1984)
"Recently, this laboratory has demonstrated an enhanced susceptibility toward the development of lethal ventricular arrhythmias occurring in response to acute posterolateral ischemia in dogs with previous anterior myocardial infarction in the presence of therapeutic serum concentrations of digoxin."	3.67	Effect of digoxin on the extent of injury and the severity of arrhythmias during acute myocardial ischemia and infarction in the dog. ( Lucchesi, BR; Lynch, JJ, 1988)
"The antiarrhythmic effect of verapamil was tested on spontaneous ventricular arrhythmias during reoxygenation after 15 min of glucose-free hypoxia and on programmed electrical stimulation-(8 stimuli + 1 or 2 extrastimuli) induced ventricular fibrillation in isolated Langendorff perfused guinea pig hearts."	3.67	Effects of verapamil on reoxygenation and programmed electrical stimulation-induced ventricular arrhythmias in the isolated heart. ( Bernabei, R; Carbonin, PU; Gambassi, G; Pahor, M, 1989)
"The effects of three calcium antagonists (diltiazem, verapamil, and nifedipine) on reperfusion-induced arrhythmias were compared in a conscious rat preparation with coronary artery occlusion and implanted electrocardiogram limb electrodes."	3.67	Reperfusion-induced arrhythmias in the conscious rat: a comparative study with three calcium antagonists. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS; Mitani, A, 1989)
" We report a patient with atrial flutter-fibrillation who developed cyclic sinus node dysfunction with profound ventricular pauses in response to small doses of digoxin, verapamil, and propranolol, which resolved with discontinuation of the medications."	3.67	Hyperthyroid-induced atrial flutter-fibrillation with profound sinoatrial nodal pauses due to small doses of digoxin, verapamil, and propranolol. ( Hurst, JW; Talley, JD; Wathen, MS, 1989)
" In two elderly manic patients taking the medication in combination with lithium carbonate, profound bradycardia developed and was followed by a fatal myocardial infarction in one case."	3.67	Verapamil: a new antimanic drug with potential interactions with lithium. ( Allen, S; Dubovsky, SL; Franks, RD, 1987)
"There is increasing evidence that the use of cocaine can trigger lethal cardiac events, including ventricular fibrillation."	3.67	Cocaine-induced ventricular fibrillation: protection afforded by the calcium antagonist verapamil. ( Billman, GE; Hoskins, RS, 1988)
"Intravenous picrotoxin injection has been established as a model of producing arrhythmias, mainly through enhanced central sympathetic outflow."	3.67	Effects of calcium-channel blockers on picrotoxin-induced centrogenic arrhythmias in cats. ( Chai, CY; Chiang, BN; Deng, JF; Hou, ZY; Kuo, JS; Liu, RH, 1988)
"Protective influence of verapamil upon ouabain-induced cardiac arrhythmias was investigated in anesthetized (alpha-chloralose 60 mg/kg and urethane 500 mg/kg) open-chest guinea pigs."	3.67	Protective effect of verapamil upon ouabain-induced cardiac arrhythmias. ( Hoeschen, RJ; Khatter, JC; Navaratnam, S, 1988)
"In this study prophylactic antiarrhythmic effects of verapamil on exercise-induced ventricular arrhythmias are evaluated."	3.67	Prophylaxis of exercise-induced ventricular arrhythmias by verapamil. ( Behrenbeck, T; Bender, F; Godejohann, U; Gülker, H; Heuer, H, 1987)
"In this study prophylactic antiarrhythmic effects of verapamil on exercise-induced ventricular arrhythmias were evaluated in a total of 22 patients."	3.67	[Prevention of effort-induced ventricular arrhythmia using verapamil]. ( Behrenbeck, T; Bender, F; Dorsel, T; Godejohann, U; Gülker, H; Heuer, H, 1987)
"This study was designed to clarify the mechanism of reperfusion arrhythmia and with the effect of verapamil on arrhythmia."	3.67	The effect of verapamil on reperfusion arrhythmia in canine heart. ( Hattori, M; Miyazaki, Y; Nagai, S; Ozawa, T; Sugiyama, S, 1985)
"The effects of verapamil and bepridil on occlusion and reperfusion ventricular arrhythmias including ventricular fibrillation (VF) were studied in a canine model."	3.67	Effects of verapamil and bepridil on occlusion and reperfusion arrhythmias in the canine heart. ( Belhassen, B; Chagnac, A; Laniado, S; Pardo, Y; Pelleg, A; Shargordsky, B, 1985)
" The present study was designed to examine the effects of calcium and verapamil on LPC-induced arrhythmias."	3.67	Effect of reduced calcium on lysophosphatidylcholine-induced cardiac arrhythmias. ( Lederman, CL; Man, RY, 1985)
"The efficacy of verapamil and lidocaine for treating ischemia-induced arrhythmias was determined in a conscious canine model with a previous myocardial infarction remote from the ischemic area."	3.67	Effects of verapamil and lidocaine in a canine model of sudden coronary death. ( Hoffman, BF; Legenza, M; Southworth, SR; Temesy-Armos, PN, 1985)
"Verapamil, a calcium channel blocking drug, terminates supraventricular arrhythmias but may have a negative inotropic effect and produce peripheral vasodilatation and hypotension."	3.66	The use of calcium with verapamil in the management of supraventricular tachyarrhythmias. ( Gotsman, MS; Halon, DA; Hasin, Y; Lewis, BS; Weiss, AT, 1983)
"Certain general conclusions suggest themselves on the basis of our extensive experience with treating arrhythmias in patients following open heart surgery, our specific results with verapamil therapy in the treatment of atrial fibrillation and atrial flutter in patients following open heart surgery, and the results of verapamil therapy administered in other groups of patients."	3.66	Verapamil therapy in the treatment of supraventricular arrhythmias following open heart surgery. ( Arciniegas, JG; Henthorn, RW; Plumb, VJ; Waldo, AL; Zimmern, SH, 1983)
" However, in vitro experiments are not satisfactory to predict antiarrhythmic activity "in vivo", because: 1) they are mostly performed in preparations made from the normal myocardium; 2) "in vitro" the autonomic and hormonal effects are absent; 3) some drugs as nitroglycerin or strophanthin do not produce antiarrhythmic electrophysiological changes in "vitro" but under appropriate conditions they may have a clear-cut antiarrhythmic action "in vivo"; 4) arrhythmias mostly arise from the interaction of changes in several fundamental electrophysiological parameters which could be best studied "in vivo"."	3.66	[Pharmacologic evaluation of electrical processes in the myocardium]. ( Sekeresh, L, 1982)
"Effects of diethyl 4-(benzothiazol-2-yl)benzylphosphonate (KB-944), a new chemical class of Ca-antagonist, on three types of experimentally induced arrhythmias were evaluated and compared with those of verapamil and diltiazem."	3.66	Antiarrhythmic effect of KB-944, a new calcium antagonist. A comparison with verapamil and diltiazem. ( Ito, K; Morita, T; Nose, T; Sukamoto, T; Yoshidomi, M, 1982)
" But when rapid control of the ventricular rate is required to arrhythmias such as atrial fibrillation, atrial flutter, or paroxysmal atrial tachycardia, a slow infusion of verapamil is the agent of choice."	3.66	Anti-arrhythmic agents in ischemic heart disease: supraventricular arrhythmias, digitalis toxicity and chronic stable ventricular ectopic beats. ( Opie, LH, 1982)
"Personal clinical experience using Verapamil intravenously in 200 patients with a number of arrhythmia conditions is reported."	3.65	[Four years of clinical experience with the cardio-eurhythmic action of verapamil in intravenous administration]. ( Malfatti, S; Piccini, A, 1975)
" It did not antagonize the deslanoside arrhythmias, but inhibited transiently the arrhythmias induced by either electrical stimulation of the posterior hypothalamus or bilateral carotid occlusion in cats."	3.65	Effect of verapamil on experimental arrhythmias. ( Huang, TF; Peng, YI, 1977)
"In 12 patients affected by acute myocardial infarction complicated only by ventricular extrasystoles, verapamil was highly effective in the control of the arrhythmias."	3.65	[The antiarrhythmic effects of verapamil in acute myocardial infarction. Considerations on the possible action mechanism (author's transl)]. ( Fazzini, PF; Marchi, F; Pucci, P, 1977)
"In vivo and in vitro experiments showed that Verapamil dilates the coronaries, prevents coronary spasm, produces Ca++-antagonism, offers protection against myocardial necrosis, prevents arrhythmia, reduces pressure, increases the purinergic reactivity and produces inhibition of platelet aggregation."	3.65	[Experimental analysis of some cardiovascular effects of Verapamil]. ( Brita, G; Caputi, AP; Chieppa, S; Coscia, L; Marmo, E; Rossi, F, 1975)
"Verapamil was administered intravenously to 250 patients aged between 14 and 85, suffering from tachyarrhythmia of various type."	3.65	[Clinical results with verapamil in intravenous administration in the emergency therapy of cardiac arrhythmias]. ( Amoroso, A, 1975)
"Rapid and slow venous infusion of various doses of Verapamil in a mixed series of 185 cases of arrhythmia since 1968 is reported."	3.65	[Anti-arrhythmic therapy with verapamil by intravenous infusion]. ( Disertori, M; Furlanello, F; Lanzetta, T; Piccolo, E; Trevi, GP, 1975)
"The effects of intravenous verapamil on the electrocardiogram in 15 patients with heart disease in sinus rhythm and in 44 patients with supraventricular and ventricular tachyarrhythmias were evaluated."	3.65	Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. ( Heng, MK; Mercer, CJ; Norris, RM; Roche, AH; Singh, BN, 1975)
"Verapamil administered by the intravenous route restored sinus rhythm in 33 out of 40 episodes of supraventricular tachycardia."	3.65	Clinical experience with verapamil. ( Hunt, D; Sloman, G; Vohra, J, 1975)
"Verapamil was administered by intravenous injection to 181 patients with various cardiac arrhythmias."	3.65	Immediate effects of intravenous verapamil in cardiac arrhythmias. ( Garrett, C; Krikler, DM; Schamroth, L, 1972)
"In the verapamil group ventricular arrhythmias increased from 25 to 33% (NS)."	2.67	Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM; Vaage-Nilsen, M, 1993)
"Verapamil caused a lower ventricular rate, but only six (19%) of the patients (n = 31) converted to sinus rhythm within 4 h (p < 0."	2.67	The effect of magnesium versus verapamil on supraventricular arrhythmias. ( Birkeland, K; Gullestad, L; Høyer, MM; Kjekshus, J; Mølstad, P; Vanberg, P, 1993)
"The incidence of conversion arrhythmias was similar in both treatment groups (adenosine 57%, verapamil 50%, p = NS)."	2.67	Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. ( Hood, MA; Smith, WM, 1992)
"Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics."	2.65	Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982)
"Ventricular arrhythmias are significantly associated with arrhythmic as well as non-arrhythmic death."	2.39	Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. ( Jespersen, CM, 1996)
"In clinical arrhythmias, the main therapeutic role of calcium channel entry blockers is related to their effect on the sinus and atrioventricular (AV) node."	2.38	Use of calcium channel entry blockers in the treatment of cardiac arrhythmias. ( Akhtar, M; Jazayeri, M; Tchou, P, 1989)
"There is a narrow margin between therapeutic and toxic doses and serum levels of digitalis glycosides."	2.37	Digitalis toxicity. ( Antman, EM; Smith, TW, 1985)
" Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level."	2.37	Antiarrhythmic drug therapy. Recent advances and current status. ( Somberg, J, 1985)
"The frequency of ventricular arrhythmias increases with age."	2.37	Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. ( Morganroth, J; Nestico, PF, 1986)
" Special consideration, however, must be given with regard to drug selection and dosage in order to avoid adverse effects on the mother and fetus."	2.36	Antiarrhythmic drug therapy during pregnancy. ( Elkayam, U; Frishman, W; Rotmensch, HH, 1983)
"Treatment with nifedipine can safely be combined with administration of a beta receptor blocking agent."	2.36	Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. ( Henry, PD, 1980)
"Their value in ventricular arrhythmias is uncertain but they are unlikely to be effective except in those complicating coronary artery spasms."	2.36	Calcium antagonists. Clinical use in the treatment of arrhythmias. ( Baky, SH; Nademanee, K; Singh, BN, 1983)
"Verapamil is a slow-channel calcium-blocking agent that has been released recently by the Food and Drug Administration for treatment of cardiac dysrhythmias in all age groups."	2.36	Verapamil: an effective calcium blocking agent for pediatric patients. ( Garson, A; Gillette, PC; Porter, CJ, 1983)
"Cardiac arrhythmias may be caused by abnormalities of impulse initiation, impulse propagation, or a combination of the two."	2.36	Electropharmacology of antiarrhythmic drugs. ( Rosen, MR; Wit, AL, 1983)
"Verapamil was the first of a class of agents known as calcium entry blockers to be released for clinical use in the United States."	2.36	The clinical use of verapamil. ( Holmes, DR; McGoon, MD; Osborn, JE; Vlietstra, RE, 1982)
"Verapamil is a novel antiarrhythmic and antianginal agent which, although introduced in 1962, has only recently gained prominence not only as a significant agent in cardiovascular therapeutics but also as a powerful tool to examine the nature of some of the biophysical phenomena at the membrane of cardiac and other excitable tissues."	2.36	Verapamil: a review of its pharmacological properties and therapeutic use. ( Ellrodt, G; Peter, CT; Singh, BN, 1978)
"In 6 patients, arrhythmias were controlled after extracorporeal membrane oxygenation (ECMO) support; 5 of these patients survived."	1.72	Cardiac crises: Cardiac arrhythmias and cardiomyopathy during TANGO2 deficiency related metabolic crises. ( Azamian, M; Beach, CM; Ceresnak, SR; Delauz, CM; Ehsan, SA; Glinton, KE; Houck, KM; Howard, TS; Janson, CM; Jardine, K; Kannankeril, PJ; Kava, M; Kim, JJ; Lalani, SR; Lay, EJ; Li, N; Liberman, L; Macicek, SL; Milewicz, DM; Miyake, CY; Pham, TD; Robertson, T; Soler-Alfonso, C; Stephens, SB; Tosur, M; Valdes, SO; Webster, G; Xu, W; Zhang, L, 2022)
"Verapamil treatment was successful in reducing defibrillator discharge frequency of the KCNQ1/TRPM4 dual mutation patient."	1.72	In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. ( Guo, Y; Han, Y; Li, Y; Liang, X; Lu, Y; Sang, W; Tang, B; Wang, F; Wang, L; Xiaokereti, J; Xing, Q; Zhang, J; Zhang, L; Zhou, X; Zukela, T, 2022)
"Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0."	1.51	Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019)
"Effects of verapamil on arrhythmias induced by Bay K8644 (a calcium channel agonist) were also determined."	1.39	Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart. ( Chen, M; Pei, JM; Wang, QL; Wu, Q; Zhang, SM; Zhou, P, 2013)
" In patients with life-saving use in suicide attempts important role in addition to medication dosage plays an elapsed time of their consumption and speed of action taken to remove and prevent absorbtion the poison", as well as close supervision in the intensive care unit."	1.38	[Drugs acting on the heart-conductive system in suicide attempts]. ( Dabek, J; Jakubowski, D; Rychlik, W; Stachoń, K, 2012)
" Seven (24%) patients presented bradycardia considered as nonserious adverse event (NSAE) and four (14%) patients presented arrhythmia (heart block) considered as serious adverse event (SAE)."	1.37	Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). ( Donnet, A; Lanteri-Minet, M; Piano, V; Silhol, F, 2011)
"Sinus arrhythmias in all MODS dogs (100%; 6 of 6) and premature ventricular beats in 4 MODS dogs (66%; 4 of 6) were recorded, while no arrhythmias were found in the control animals."	1.36	Investigation of the alterations in cellular electrophysiology underlying ventricular arrhythmia in dogs with the multiple organ dysfunction syndrome. ( Bin, Y; Hou, YM; Juan, S; Liu, ZJ; Ping, F; Song, JG; Ullah, S; Yang, H; Zang, XQ, 2010)
"Cerebral ischemic model was made by middle cerebral artery occlusion (MCAO)."	1.35	Aberration of L-type calcium channel in cardiac myocytes is one of the mechanisms of arrhythmia induced by cerebral ischemia. ( Du, J; Pan, G; Sun, L; Wang, L; Yang, B; Zhang, G; Zhang, Y, 2008)
"The management of arrhythmias during pregnancy is, in principle, similar to that in nonpregnant patients, however, special consideration must be given, to avoid adverse fetal effects."	1.31	[Treatment of cardiac arrhythmia in pregnant women]. ( Halawa, B, 2000)
"Infarct, arrhythmia, heart rate and coronary artery flow were determined in hearts treated with vehicle, RST extract, Tet, Fan, or verapamil."	1.31	Cardiac effects of the extract and active components of radix stephaniae tetrandrae. II. Myocardial infarct, arrhythmias, coronary arterial flow and heart rate in the isolated perfused rat heart. ( Chen, CF; Pang, KT; Shan, J; Wang, GY; Wong, TM; Wu, S; Yu, XC, 2001)
"Bupivacaine is a local anesthetic frequently used in clinical practice, and cardiotoxicity is one of its severe side effects."	1.30	The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study. ( Adsan, H; Onaran, O; Tulunay, M, 1998)
"Verapamil was injected intravenously via a catheter inserted into the internal jugular vein in doses of 0."	1.30	Effects of verapamil on bladder instability induced by partial outflow obstruction in rat. ( Kondo, A; Saito, M, 1998)
"Pretreatment with lidocaine (5 mg/kg), verapamil (0."	1.30	Ischemia/reperfusion-induced arrhythmias in anaesthetized rats: a role of Na+ and Ca2+ influx. ( Dai, DZ; De Clerck, F; Lu, HR; Remeysen, P; Saels, A; Yang, P, 1999)
"Thus verapamil was more efficacious than anipamil at providing antiarrhythmic protection against both early and late onset arrhythmias."	1.29	Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. ( Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995)
" The rats were observed for toxic signs and survival over a period of 15 days."	1.29	Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats. ( Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1996)
"Mibefradil is a new calcium antagonist that can inhibit cardiac calcium current without reducing myocardial force development."	1.29	The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. ( Billman, GE; Hamlin, RL, 1996)
"Ventricular arrhythmias were observed in 5 of 7, 6 of 7, and 7 of 7 preparations exposed to 0."	1.28	Potential cellular mechanisms of hydrogen peroxide-induced cardiac arrhythmias. ( Duan, J; Moffat, MP, 1992)
"Arrhythmias were associated with prolongation of transmural conduction time (CT) and abbreviation of endocardial effective refractory period."	1.28	Verapamil prevents slowing of transmural conduction and suppresses arrhythmias in an isolated guinea pig ventricular model of ischemia and reperfusion. ( Ferrier, GR; Li, GR, 1992)
"To test the hypothesis that such arrhythmias may be mediated by sarcolemmal stretch-activated channels, we attempted to inhibit stretch-induced arrhythmias with gadolinium (Gd3+), a potent stretch-activated channel blocker."	1.28	Dose-dependent inhibition of stretch-induced arrhythmias by gadolinium in isolated canine ventricles. Evidence for a unique mode of antiarrhythmic action. ( Borganelli, M; Hansen, DE; Stacy, GP; Taylor, LK, 1991)
"Verapamil suppressed the arrhythmia which further indicates the non-ventricular origin of these wide QRS complexes."	1.28	[Supraventricular arrhythmia imitating ventricular ectopy due to simultaneous conduction in dual AV nodal pathways--a therapeutic problem]. ( Prochaczek, F, 1990)
"DESIGN - Ventricular arrhythmias were studied in isolated rat hearts (n = 8-15 per experiment) subjected to regional ischaemia and treated with various free radical scavengers and spin trap agents."	1.28	Reperfusion damage: free radicals mediate delayed membrane changes rather than early ventricular arrhythmias. ( Coetzee, WA; Dennis, SC; Opie, LH; Owen, P; Saman, S, 1990)
" The mean nontoxic dose was 320 mg, whereas the mean toxic ingestion was 3."	1.28	Calcium channel blocker toxicity. ( Myers, A; Ramoska, EA; Spiller, HA, 1990)
"When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide."	1.28	[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989)
"From these results we conclude that arrhythmia is preceded by a state of deteriorated epicardial activation pattern (prearrhythmia), which can be quantitatively evaluated and used for detection of preventive antiarrhythmic drug action."	1.28	The potential of epicardial activation mapping in isolated hearts for the assessment of arrhythmogenic and antiarrhythmic drug activity. ( Dhein, S; Klaus, W; Müller, A, 1989)
"Adrenergic arrhythmias were induced in isolated rat hearts with epinephrine in a concentration of 5."	1.28	[Prevention of adrenaline-induced arrhythmia by a calmodulin blocker, trifluoroperazine]. ( Karpov, RS; Larionov, NP; Malyshev, IIu; Meerson, FZ, 1989)
"Our current understanding of human cardiac arrhythmias is primitive and their treatment is largely empirical."	1.27	Perspectives on the current treatment of cardiac arrhythmias. ( Bigger, JT, 1984)
"Twenty-six patients had no ventricular arrhythmias in 633 ischemic attacks; 16 patients had ventricular arrhythmias in 116/586 ischemic attacks."	1.27	[Characterization and therapy of ventricular arrhythmias due to transient myocardial ischemic attacks in variant angina]. ( Dini, P; Prati, PL; Rocca, P; Turitto, G; Vicari, M; Zanchi, E, 1984)
"Ventricular arrhythmias were classified in a modified Lown classification: 1."	1.27	[Risk of stress-induced ventricular arrhythmias in hypertrophic cardiomyopathy]. ( Borggrefe, M; Christoph, I; Königer, HH; Lösse, B, 1984)
"Digoxin levels were twice as high in plasma, heart, liver and muscle of verapamil pretreated rats (p less than 0."	1.27	Verapamil and digoxin: interactions in the rat. ( Genchik, G; Kaplanski, J; Topaz, M; Weinhouse, E, 1983)
"Phenytoin was effective on three arrhythmias and its min PCs were 9."	1.27	Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations. ( Hashimoto, K; Imai, S; Satoh, H; Shibuya, T, 1983)
"This arrhythmia, similar to the more common uniform AIVR, was intermittent, did not cause hemodynamic compromise, and was not related to more serious ventricular arrhythmias."	1.27	Multiform accelerated idioventricular rhythm in acute myocardial infarction: electrocardiographic characteristics and response to verapamil. ( Agmon, J; Arditi, A; Fuchs, J; Klainman, E; Kracoff, OH; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983)
"They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon."	1.27	Calcium channel blocking drugs. Part II: Clinical applications. ( Brill, DM; Fozzard, HA, 1985)
"The mechanisms underlying the cause of sudden death have not been clearly elucidated."	1.27	[Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences]. ( Kleinebenne, A; McKenna, WJ, 1985)
"The treatment of hypertrophic cardiomyopathy is first and foremost symptomatic, its aim being to counteract dyspnea, angina pectoris, syncopes and lipothymias, palpitations."	1.27	[Treatment of hypertrophic cardiomyopathy]. ( Bouhour, JB; Lefèvre, M; Letard, G, 1985)
"When used in conjunction with raw arrhythmia data, comprehensive drug dose ranges, and appropriate parametric statistical tests, arrhythmia scores facilitate the quantification of arrhythmias."	1.27	Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. ( Curtis, MJ; Walker, MJ, 1988)
"Models of ischemic and reperfusion arrhythmias were reproduced in isolated rat hearts by means of the ligation and subsequent reocclusion of the left descending coronary artery."	1.27	[Prevention of ischemic and reperfusion arrhythmias using the calmodulin blocker trifluoperazine]. ( Karpov, RS; Larionov, NP; Malyshev, IIu; Meerson, FZ, 1988)
"Verapamil was more effective than diltiazem."	1.27	Comparison of the effects of calcium channel blockers and antiarrhythmic drugs on digitalis-induced oscillatory afterpotentials on canine Purkinje fiber. ( Endou, K; Sato, T; Yamamoto, H, 1987)
"Correspondingly, ventricular arrhythmias and fibrillation were almost completely prevented by metoprolol, d-sotalol or verapamil, but increased by lidocaine."	1.27	Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion. ( Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987)
"Bepridil has both slow channel blocking properties and fast channel blocking effects and thus possesses an antiarrhythmic effect beyond the prolongation of repolarization."	1.27	Calcium channel blockers that prolong the QT interval. ( Somberg, JC, 1985)
"Bepridil has been shown to block both slow- and fast-channel activity in the heart."	1.27	Electrophysiologic and antiarrhythmic properties of bepridil. ( Prystowsky, EN, 1985)
"Fetal cardiac arrhythmias are usually first suspected on the basis of auscultatory findings during routine examination in pregnancy."	1.27	Treatment of fetal cardiac arrhythmias. ( Stewart, PA; Wladimiroff, JW, 1985)
"Amiodarone was the only one of the four drugs that caused a substantial reduction of ventricular premature complexes (logarithmic mean 97."	1.27	Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. ( Bandieri, JD; Chiale, PA; Elizari, MV; Haedo, AH; Lázzari, JO; Rosenbaum, MB, 1986)
"In three fetuses no arrhythmia was identified."	1.27	Two-dimensional and M-mode echocardiographic evaluation of fetal arrhythmia. ( Crowley, DC; Dick, M; Rayburn, WF; Rosenthal, A, 1985)
"The effects of verapamil on ventricular arrhythmias and free fatty acids metabolism during coronary artery reperfusion in experimental dogs were evaluated over a period of 40 minutes and followed by reperfusion for 15 minutes."	1.27	Antiarrhythmic and myocardial metabolic effects of verapamil during coronary artery reperfusion. ( Abe, M; Hayashi, H; Ishizaka, K; Kamikawa, T; Kobayashi, A; Nagao, B; Nishiyama, T; Yamashita, T; Yamazaki, N, 1985)
"Benign postoperative arrhythmias occur, but at hospital discharge, few conduction abnormalities (10%) persist."	1.27	Verapamil potassium cardioplegia and cardiac conduction. ( DeWeese, JA; Hicks, GL, 1985)
"The arrhythmias were prevented by higher doses of the calcium antagonist verapamil which, however, decreased the survival times."	1.26	Comparative investigation of the effects of metoprolol, propranolol, practolol, and verapamil in the acute phase of experimental myocardial infarction. ( Bernauer, W, 1982)
"The arrhythmia was refractory to lidocaine and procainamide and only responded dramatically to verapamil, initially intravenous and afterwards oral."	1.26	"Torsades de pointes" invariant angina: successful treatment with verapamil. ( Cokkinos, DV; Koroxenidis, G; Tolis, G; Vorides, EM, 1981)
"A ventricular tachyarrhythmia develops when these hearts are allowed to repolarize in 1."	1.26	Experimental arrhythmia elicited by low K perfusion. ( Blaney, R; Chartier, D; Ponce-Zumino, A; Ruiz-Ceretti, E, 1982)
"Bunaftine was the antiarrhythmic drug more frequently used (23 cases, 34%) with a high percentage of success (87%)."	1.26	[Mobile coronary unit of Florence: early care of arrhythmias not due to acute coronary insufficiency]. ( Barletta, GA; Bertini, G; Conti, A; Fattirolli, F; Giuntini, F; Mangialavori, G; Margheri, M; Mazzoni, D; Vannelli, P, 1982)
"A general discussion of arrhythmias as followed by a brief description of two of the commonly encountered dysrhythmias in the pediatric age group, i."	1.26	Arrhythmias in infants and children. ( Shakibi, JG, 1981)
"Verapamil failed to produce a consistent shift in the membrane responsiveness curve (Vmax versus take-off membrane potentials), although the development of early, slow action potentials was blocked."	1.26	Effects of verapamil on action potentials of Purkinje fibers. ( Dersham, GH; Han, J, 1980)
"Reentrant ventricular arrhythmias (RVA) were analyzed in dogs 3--7 days after ligation of the anterior descending coronary artery using averaged "composite" recordings of electrical activity of reentrant pathways (RP) from the epicardial surface of the infarction zone (IZ)."	1.26	Reentrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of verapamil and D-600 and the role of the "slow channel". ( El-Sherif, N; Lazzara, R, 1979)
"In half of the patients with tachyarrhythmia."	1.26	[Treatment of acute left-ventricular insufficiency complicated by tachyarrhythmia under conditions of cardiological emergency service]. ( Danilenko, AM; Rodionov, VM; Zakharova, RM, 1979)
"The effects of the drug suggest that arrhythmia seems to be due to an interplay of sympathetic and parasympathetic influences with the latter effect predominating."	1.26	Cardiac arrhythmia induced by electrical stimulation of the fastigial nucleus in cats. ( Huang, TF, 1977)
"Verapamil was infused (20 microgram/kg/min) until the escape interval increased at least 50% or until the AVE was abolished."	1.26	Effect of autonomic neural blockade on verapamil-induced suppression of the accelerated ventricular escape beat in ouabain-treated dogs. ( Kelly, RJ; Klevans, LR, 1978)
"The incidence of ventricular arrhythmias was increased by aprindine (from 1 in 11 to 8 in 11 dogs), decresed by verapamil (from 3 in 7 to 0 in 7 dogs) and was not changes by quinidine or isoproterenol."	1.26	Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. ( Elharrar, V; Gaum, WE; Zipes, DP, 1977)
"Verapamil has a lowering effect on the blood pressure even in the presence of advanced renal failure."	1.26	[The treatment of renal hypertension with verapamil in childhood (author's transl]. ( Alatas, H; Bein, G; Schärer, K, 1977)
"(-)Verapamil has no comparable effects on the excitability of the atrial myocardium."	1.26	Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil. ( Raschack, M, 1976)
"Verapamil is a new anti-anginal and anti-arrhythmic drug whose pharmacological actions can be related to its specific blocking effect on the transmembrane transport of calcium ions."	1.25	Verapamil and the heart: Pharmacological and Therapeutic Considerations. ( DPhil, BN, 1975)
"Verapamil was administered i."	1.25	[Venous infusion of nerapamil in the treatment of refractory angina pectoris and arrhythmia due to associated electric instability]. ( Furlanello, F; Lanzetta, T; Pascotto, P; Piccolo, E; Trevi, GP, 1975)
"Verapamil was initially known for its anti-angina effect."	1.25	[Verapamil: an original anti-arrhythmic agent]. ( Baissus, C; Puech, P, 1975)
"In this age group most of the occurring cardiac arrhythmias are harmless and pass without serious circulatory disturbances."	1.25	[Treatment of heart-rhythm disorders in infancy and childhood]. ( Eschenbacher, HL; Gutheil, H; Singer, H, 1975)

Research

Studies (574)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Number of Participants With Dose Limiting Toxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	437 (76.13)	18.7374
1990's	82 (14.29)	18.2507
2000's	28 (4.88)	29.6817
2010's	20 (3.48)	24.3611
2020's	7 (1.22)	2.80

Authors	Studies
Nihro, Y	1
Sogawa, S	1
Izumi, A	1
Sasamori, A	1
Sudo, T	1
Miki, T	1
Matsumoto, H	1
Satoh, T	1
Jia, L	1
Sun, H	1
Li, Y	2
Zhang, HB	1
Huang, WL	1
Li, YM	1
Editorial, A	1
Miyake, CY	1
Lay, EJ	1
Beach, CM	1
Ceresnak, SR	1
Delauz, CM	1
Howard, TS	1
Janson, CM	2
Jardine, K	1
Kannankeril, PJ	1
Kava, M	1
Kim, JJ	1
Liberman, L	1
Macicek, SL	1
Pham, TD	1
Robertson, T	1
Valdes, SO	1
Webster, G	1
Stephens, SB	1
Milewicz, DM	1
Azamian, M	1
Ehsan, SA	1
Houck, KM	1
Soler-Alfonso, C	1
Glinton, KE	1
Tosur, M	1
Li, N	1
Xu, W	1
Lalani, SR	1
Zhang, L	2
Clark, AP	1
Wei, S	1
Kalola, D	1
Krogh-Madsen, T	1
Christini, DJ	1
Wang, F	1
Han, Y	1
Sang, W	1
Wang, L	3
Liang, X	1
Xing, Q	1
Guo, Y	1
Zhang, J	3
Zukela, T	1
Xiaokereti, J	1
Lu, Y	1
Zhou, X	1
Tang, B	1
Seo, K	1
Yamamoto, Y	1
Kirillova, A	1
Kawana, M	1
Yadav, S	1
Huang, Y	1
Wang, Q	1
Lane, KV	1
Pruitt, BL	1
Perez, MV	1
Bernstein, D	1
Wu, JC	1
Wheeler, MT	1
Parikh, VN	1
Ashley, EA	1
Zvizdic, F	1
Begic, E	1
Mujakovic, A	1
Hodzic, E	1
Prnjavorac, B	1
Bedak, O	1
Custovic, F	1
Bradaric, H	1
Durak-Nalbantic, A	1
Bai, S	1
Pei, J	1
Chen, K	1
Zhao, Y	1
Cao, H	1
Tian, L	1
Ma, Y	1
Dong, H	1
Pravdin, SF	1
Epanchintsev, TI	1
Panfilov, AV	1
Watanabe, H	1
Honda, Y	1
Deguchi, J	1
Yamada, T	1
Bando, K	1
Tegethoff, AM	1
Raney, E	1
Mendelson, J	1
Minckler, MR	1
Stokke, MK	1
Tovsrud, N	1
Louch, WE	1
Øyehaug, L	1
Hougen, K	1
Sejersted, OM	1
Swift, F	1
Sjaastad, I	1
Yesmine, S	1
Connolly, K	1
Hill, N	1
Coulson, FR	1
Fenning, AS	1
Zhou, P	1
Zhang, SM	1
Wang, QL	1
Wu, Q	1
Chen, M	1
Pei, JM	1
Poelzing, S	1
Shah, MJ	1
Koncz, I	1
Gurabi, Z	1
Patocskai, B	1
Panama, BK	1
Szél, T	1
Hu, D	1
Barajas-Martínez, H	1
Antzelevitch, C	2
Khori, V	1
Alizadeh, AM	1
Moheimani, HR	1
Zahedi, M	1
Aminolsharieh Najafi, S	1
Shakiba, D	1
Nayebpour, M	1
Srikrishna, G	1
Gupta, S	1
Dooley, KE	1
Bishai, WR	1
Tanel, RE	1
Grant, EK	1
Berul, CI	1
Sokhanenkova, AE	1
Sokhanenkov, MIu	1
Afanas'eva, EIu	1
Arzamastsev, EV	1
Sun, L	1
Du, J	1
Zhang, G	1
Zhang, Y	1
Pan, G	1
Yang, B	1
Chen, CX	1
Zhang, HY	1
Das, MK	1
Hou, YM	1
Song, JG	1
Juan, S	1
Ullah, S	1
Bin, Y	1
Zang, XQ	1
Ping, F	1
Yang, H	1
Liu, ZJ	1
Feng, C	1
Li, BG	1
Gao, XP	1
Qi, HY	1
Zhang, GL	1
Lanteri-Minet, M	1
Silhol, F	1
Piano, V	1
Donnet, A	1
Lu, WJ	1
Zhou, J	2
Ma, HY	1
Lü, GH	1
You, FQ	1
Ding, AW	1
Duan, JA	1
Ma, H	1
Shang, E	1
Lu, W	1
Zhan, Z	1
Qian, D	1
Duan, J	2
Fan, X	1
Dabek, J	1
Stachoń, K	1
Jakubowski, D	1
Rychlik, W	1
Kasprzak, JD	1
Stępińska, J	1
Wożakowska Kapłon, B	1
Drożdż, J	1
Grajek, S	1
Opolski, G	1
Rynkiewicz, A	1
Tykarski, A	1
Filipiak, KJ	1
Cheung, BM	1
Kumana, CR	1
White, WB	1
LaRocca, GM	1
Maron, BJ	3
McKenna, WJ	5
Danielson, GK	1
Kappenberger, LJ	1
Kuhn, HJ	1
Seidman, CE	1
Shah, PM	1
Spencer, WH	1
Spirito, P	1
Ten Cate, FJ	1
Wigle, ED	1
Petrov, VI	1
Spasov, AA	1
Anisimova, VA	1
Kirillov, OV	1
Yu, XC	2
Wu, S	2
Chen, CF	2
Pang, KT	2
Wong, TM	2
Nedostup, AV	1
Blagova, OV	1
Bogdanova, EA	1
Platonova, AA	1
Circosta, C	1
De Pasquale, R	1
Occhiuto, F	1
Kocic, I	1
Fish, JM	1
Welchons, DR	1
Kim, YS	1
Lee, SH	1
Ho, WK	1
Tanabe, Y	1
Hatada, K	1
Naito, N	1
Aizawa, Y	2
Chinushi, M	1
Nawa, H	1
Ito, I	1
Hayashi, Y	2
Kawai, Y	1
Iwasaki, M	1
Takada, K	2
Kamibayashi, T	2
Yamatodani, A	2
Mashimo, T	1
de Diego, C	1
Chen, F	1
Xie, LH	1
Dave, AS	1
Thu, M	1
Rongey, C	1
Weiss, JN	1
Valderrábano, M	1
Marsh, E	1
O'Callaghan, P	1
Smith, P	1
Kolloch, R	1
Legler, UF	1
Champion, A	1
Cooper-Dehoff, RM	1
Handberg, E	1
Zhou, Q	1
Pepine, CJ	1
Bender, F	9
Stone, KS	1
Scordo, KA	1
Opie, LH	4
Karagueuzian, HS	1
Katzung, BG	1
Karlsberg, RP	3
Hunt, D	3
Kertes, P	1
Bernauer, W	2
Gottdiener, JS	1
DiBianco, R	1
Fletcher, RD	1
Leclercq, JF	1
Georgiopoulos, G	1
Halkidis, H	1
Attuel, P	1
Maisonblanche, P	1
Coumel, P	2
Lüderitz, B	1
Krikler, DM	9
Rowland, E	4
Rotmensch, HH	1
Elkayam, U	1
Frishman, W	1
Vanhaleweyk, GL	1
Serruys, PW	1
Hugenholtz, PG	1
Ellrodt, AG	1
Singh, BN	13
Runge, M	1
Bigger, JT	1
Mortara, D	1
Divers, T	1
Woosley, RL	1
Roden, DM	1
Duff, HJ	1
Oates, JA	1
Frishman, WH	1
LeJemtel, TH	1
Wainwright, R	1
Crick, J	1
Sowton, E	2
Ellrodt, G	2
Chew, CY	1
Henry, PD	1
Antman, EM	3
Stone, PH	1
Muller, JE	1
Braunwald, E	1
Lazzara, R	3
Scherlag, B	1
Horwitz, DL	1
Ribeiro, LG	4
Brandon, TA	3
Debauche, TL	2
Maroko, PR	3
Miller, RR	3
Russell, DC	1
Surawicz, B	1
Motté, G	1
Zipes, DP	7
Gilmour, RF	2
Bianchi, CP	1
Gould, RJ	1
Murphy, KM	1
Reynolds, IJ	1
Snyder, SH	1
Covinsky, JO	1
Hamburger, SC	1
Tullio, D	1
Valerio, A	1
D'Agostino, F	1
Nademanee, K	5
Baky, SH	1
Porter, CJ	1
Garson, A	2
Gillette, PC	1
Seipel, L	2
Breithardt, G	2
Borggrefe, M	2
Feld, G	2
Martin, GB	2
Nowak, RM	1
Emerman, CL	1
Tomlanovich, MC	1
Pine, RM	1
Amoroso, A	2
Lanciotti, G	1
Mammarella, A	1
Ostapiuk, FE	1
Khvoinitskiĭ, VA	1
Moenning, SP	1
Josephson, MA	1
Ikeda, N	1
Venkatesh, N	1
Kannan, R	1
Rosen, MR	4
Wit, AL	3
Hope, RR	1
Rozanski, GJ	2
Jalife, J	2
Moe, GK	1
Fagbemi, O	1
Kane, KA	1
McDonald, FM	1
Parratt, JR	1
Rothaul, AL	1
Curtis, MJ	3
MacLeod, BA	1
Walker, MJ	4
Halawa, B	2
Babich, M	1
Hamann, SR	1
McAllister, RG	1
Pratap Reddy, C	1
Piascik, MT	1
Gülker, H	5
Thale, J	3
Brisse, B	1
Nakaya, H	3
Ozaki, S	1
Kimura, S	3
Gotoh, Y	1
Kanno, M	2
Onuaguluchi, G	2
Tanz, RD	1
Dick, M	2
Campbell, RM	1
Turitto, G	1
Dini, P	2
Rocca, P	1
Vicari, M	1
Zanchi, E	1
Prati, PL	1
Dimitrov, D	1
Dzhurdzhev, A	1
Batalov, Z	1
Gŭlŭbov, Z	1
Kichukov, N	1
Lösse, B	1
Christoph, I	1
Königer, HH	1
Hicks, GL	2
Salley, RK	1
DeWeese, JA	2
Theisen, K	1
Scheininger, M	1
Galle, JS	1
Weiss, AT	1
Lewis, BS	2
Halon, DA	1
Hasin, Y	1
Gotsman, MS	2
Borbola, J	1
Waldo, AL	1
Plumb, VJ	1
Arciniegas, JG	1
Henthorn, RW	1
Zimmern, SH	1
Jordaens, L	1
Clement, DL	1
Colardyn, F	1
Kaplanski, J	1
Weinhouse, E	1
Topaz, M	1
Genchik, G	1
Georgiev, S	1
Khadzhipetrov, N	1
Iordanov, E	1
Heuer, H	3
Meyer, M	1
Weiss, U	1
Bendeer, F	1
Hamer, AW	1
Zaher, CA	1
Peter, T	2
Mandel, WJ	3
Schwartz, JB	1
Jeang, M	1
Raizner, AE	1
Griffin, JC	1
Wyndham, CR	1
Bergey, JL	2
Wendt, RL	1
Nocella, K	2
McCallum, JD	2
Kapur, PA	2
Norel, E	1
Dajee, H	1
Cimochowski, G	1
Hluchý, J	1
Chynoradská, E	1
Pavlovic, M	1
Wu, D	1
Vohra, J	3
Reves, JG	1
Kissin, I	1
Lell, WA	1
Tosone, S	1
Severi, S	1
Davies, G	1
Maseri, A	1
Marzullo, P	1
L'Abbate, A	1
Benchimol, A	1
Desser, KB	1
Hess, D	1
Keefe, DL	2
Kates, RE	1
Harrison, DC	2
Prystowsky, EN	2
Heger, JJ	1
Sekeresh, L	1
Hashimoto, K	4
Shibuya, T	2
Satoh, H	2
Imai, S	2
Dipalma, JR	1
Friesen, RM	1
Bonet, JF	1
Sclarovsky, S	1
Strasberg, B	1
Fuchs, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190]	Phase 1	6 participants (Actual)	Interventional	2017-06-05	Terminated (stopped due to Phase II funding not available)
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]		29 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Evidence that the dose is insufficient.)
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy[NCT04133532]	Phase 4	22 participants (Actual)	Interventional	2020-03-05	Completed
Correlation Between Myocardial Deformation and Coronary Artery Morphology in Patients With Hypertrophic Cardiomyopathy and Analysis of Genetic Factors：A Prospective, Single-center, Case-control Study[NCT04830787]		302 participants (Actual)	Observational	2017-12-01	Completed
INternational VErapamil SR Trandolapril STudy[NCT00133692]	Phase 4	22,000 participants	Interventional	1997-09-30	Completed
Effects of Artificial Intelligence Assisted Follow-up Strategy Based on a New Remote Contactless Sleep Monitoring System on Secondary Prevention in Patients Received Coronary Artery Bypass Grafting Surgery[NCT04636996]		200 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674]		15,000 participants (Anticipated)	Observational	2015-01-31	Not yet recruiting
Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.[NCT00413712]	Phase 4	206 participants	Interventional	1997-01-31	Completed
Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073]	Phase 2	2 participants (Actual)	Interventional	2012-04-30	Completed
"Automated External Defibrillator (AED) Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named One Shock Per Minute"[NCT00139542]	Phase 3	5,107 participants (Actual)	Interventional	2005-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks

Diastolic Blood Pressure

Heart Rate

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Intervention	Participants (Count of Participants)
Phase Ib	0

Intervention	mmHg (Mean)
Treatment	-0.6
Control	1

Intervention	beats per minute (Mean)
Treatment	-1.4
Control	4

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Intervention	units on a scale (Least Squares Mean)
Treatment	-1.3
Control	-0.25

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Intervention	units on a scale (Mean)
Treatment	12.5
Control	17.7

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Intervention	units on a scale (Least Squares Mean)
Treatment	-44.03
Control	-6.07

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Systolic Blood Pressure

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Intervention	units on a scale (Least Squares Mean)
Treatment	-27.3
Control	0.4

Intervention	mmHg (Mean)
Treatment	-4.5
Control	-6.6

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	64.3	35.0	90.0	16.7

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Change in Number of Absence Seizures From Week 8 (Baseline) to Week 12

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	31.8	24.14	72.00	8.00

The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12

Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit

Intervention	Abscence seizures (Number)
Week 8 Baseline	165
Week 12 Verapamil 4mg/kg/Day	101

The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

Change in Number of Myoclonic Seizures From Week 8 (Baseline) to Week 12

Intervention	General tonic-clonic seizures (Number)
Week 8 Baseline	39
Week 12 Verapamil 4mg/kg/Day	14

The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

Article	Year
Chronopharmacology of cardiovascular therapy. Blood pressure monitoring, 2002, Volume: 7, Issue:4 Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Blood Pressu	2002
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S Journal of the American College of Cardiology, 2003, Nov-05, Volume: 42, Issue:9 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial;	2003
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S Journal of the American College of Cardiology, 2003, Nov-05, Volume: 42, Issue:9 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial;	2003
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S Journal of the American College of Cardiology, 2003, Nov-05, Volume: 42, Issue:9 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial;	2003
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S Journal of the American College of Cardiology, 2003, Nov-05, Volume: 42, Issue:9 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Pacing, Artificial;	2003
Modulators of ion channels activated by hypotonic swelling in cardiomyocytes: new perspectives for pharmacological treatment of life-threatening arrhythmias. Current medicinal chemistry. Cardiovascular and hematological agents, 2005, Volume: 3, Issue:4 Topics: Arrhythmias, Cardiac; Colforsin; Heart; Humans; Intercellular Signaling Peptides and Proteins; Ion C	2005
The humble electrocardiogram. Practical neurology, 2008, Volume: 8, Issue:1 Topics: Anticonvulsants; Arrhythmias, Cardiac; Brain Diseases; Electrocardiography; Heart; Humans; Nervous S	2008
Understanding the calcium channel blockers. Heart & lung : the journal of critical care, 1984, Volume: 13, Issue:5 Topics: Action Potentials; Angina Pectoris; Animals; Arrhythmias, Cardiac; Arteriosclerosis; Calcium; Calciu	1984
Effects of antiarrhythmic agents on cardiac function. Angiology, 1982, Volume: 33, Issue:4 Topics: Adrenergic beta-Antagonists; Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Car	1982
Clinical value of calcium antagonists in treatment of cardiovascular disorders. Journal of the American College of Cardiology, 1983, Volume: 1, Issue:1 Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calciu	1983
Antiarrhythmic drug therapy during pregnancy. Annals of internal medicine, 1983, Volume: 98, Issue:4 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Breast Feeding; Digitalis	1983
Anti-anginal, electrophysiologic and hemodynamic effects of combined beta-blocker/calcium antagonist therapy. European heart journal, 1983, Volume: 4 Suppl D Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Drug T	1983
Clinical applications of slow channel blocking compounds. Pharmacology & therapeutics, 1983, Volume: 23, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium	1983
[Therapy of arrhythmia during pregnancy]. Deutsche medizinische Wochenschrift (1946), 1984, Jun-15, Volume: 109, Issue:24 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biotransformation; Coumar	1984
Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. The American journal of cardiology, 1980, Dec-01, Volume: 46, Issue:6 Topics: Angina Pectoris; Angina Pectoris, Variant; Animals; Arrhythmias, Cardiac; Benzazepines; Calcium; Car	1980
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Annals of internal medicine, 1980, Volume: 93, Issue:6 Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B	1980
Electrophysiology and antiarrhythmic effects of calcium antagonists. Scottish medical journal, 1981, Volume: 26, Issue:2 Topics: Action Potentials; Arrhythmias, Cardiac; Calcium Channel Blockers; Electrophysiology; Heart; Humans;	1981
Management of arrhythmias with "calcium antagonists". Angiology, 1982, Volume: 33, Issue:8 Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Calcium; Calcium C	1982
Clinical pharmacology of calcium entry blockers. Cardiovascular clinics, 1983, Volume: 14, Issue:1 Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Diltiazem; Humans; Ion Cha	1983
Slow channel blockers. Southern medical journal, 1983, Volume: 76, Issue:1 Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Cons	1983
[Calcium antagonists in cardiology]. La Clinica terapeutica, 1983, Jan-15, Volume: 104, Issue:1 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Coronary Disease; Dilt	1983
Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs, 1983, Volume: 25, Issue:2 Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calcium Channel Blockers; Death,	1983
Verapamil: an effective calcium blocking agent for pediatric patients. Pediatrics, 1983, Volume: 71, Issue:5 Topics: Administration, Oral; Adult; Aged; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiomy	1983
[Anti-arrhythmic therapy with calcium antagonists]. Der Internist, 1983, Volume: 24, Issue:7 Topics: Arrhythmias, Cardiac; Benzazepines; Bradycardia; Calcium Channel Blockers; Digitalis Glycosides; Dil	1983
Antiarrhythmic effects of verapamil. Angiology, 1983, Volume: 34, Issue:9 Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; At	1983
Calcium-channel blocking agents: current indications and potential uses. Clinical therapeutics, 1984, Volume: 6, Issue:3 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem; Drug Interactions; Humans; Nifedipine; Ve	1984
[Calcium antagonists. Properties and current indications]. Recenti progressi in medicina, 1984, Volume: 75, Issue:4 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diltiaze	1984
Digitalis toxicity: a review of the literature. Indiana medicine : the journal of the Indiana State Medical Association, 1984, Volume: 77, Issue:11 Topics: Absorption; Arrhythmias, Cardiac; Digitalis Glycosides; Digoxin; Heart; Humans; Kinetics; Male; Nife	1984
The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions. Annals of the New York Academy of Sciences, 1984, Volume: 432 Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Drug Interactions; F	1984
Electropharmacology of antiarrhythmic drugs. American heart journal, 1983, Volume: 106, Issue:4 Pt 2 Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide	1983
The clinical uses of calcium antagonists. Advances in internal medicine, 1982, Volume: 27 Topics: Angina Pectoris; Angina Pectoris, Variant; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B	1982
Verapamil in cardiac arrhythmias: an overview. Clinical and experimental pharmacology & physiology. Supplement, 1982, Volume: 6 Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blo	1982
Calcium entry blockers: uses and implications for anesthesiologists. Anesthesiology, 1982, Volume: 57, Issue:6 Topics: Anesthesia, General; Animals; Arrhythmias, Cardiac; Biotransformation; Calcium Channel Blockers; Cor	1982
New antiarrhythmic drugs: their place in therapy. Drugs, 1981, Volume: 22, Issue:5 Topics: Action Potentials; Ajmaline; Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Aprindine; Arrhy	1981
Calcium antagonists. American heart journal, 1980, Volume: 99, Issue:6 Topics: Action Potentials; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Bronchial Spasm;	1980
[Indications for use of calcium antagonists]. Medizinische Klinik, 1980, Apr-11, Volume: 75, Issue:8 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Coronary Disease	1980
[Utilization of anti-arrhythmic drugs]. Schweizerische medizinische Wochenschrift, 1980, Jul-19, Volume: 110, Issue:29 Topics: Action Potentials; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Digital	1980
The clinical use of intravenous verapamil. American heart journal, 1980, Volume: 100, Issue:6 Pt 2 Topics: Angina Pectoris, Variant; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioventricula	1980
Hypertrophic cardiomyopathy: an overview. Clinical and investigative medicine. Medecine clinique et experimentale, 1980, Volume: 3, Issue:1-2 Topics: Adolescent; Adult; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathy, Hypertrophic; Child; Child,	1980
[Pharmacological aspects and therapeutic uses of verapamil and related calcium antagonists (author's transl)]. Revista medica de Chile, 1980, Volume: 108, Issue:10 Topics: Animals; Arrhythmias, Cardiac; Calcium; Coronary Circulation; Coronary Disease; Electrocardiography;	1980
Role of calcium antagonists in cardiovascular therapy. British heart journal, 1981, Volume: 46, Issue:1 Topics: Angina Pectoris; Arrhythmias, Cardiac; Blood Vessels; Calcium; Calcium Channel Blockers; Cardiomyopa	1981
The natural history of hypertrophic cardiomyopathy. Current problems in cardiology, 1981, Volume: 6, Issue:4 Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Death, Sudden; Humans; Nifedipine; P	1981
Clinical pharmacology of antiarrhythmic drugs: a review and overview, Part III. International journal of clinical pharmacology, therapy, and toxicology, 1981, Volume: 19, Issue:6 Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Humans; Verapamil	1981
[Progress in arrhythmology]. Giornale italiano di cardiologia, 1981, Volume: 11 Suppl 1 Topics: Adolescent; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Cardiac P	1981
The clinical use of verapamil. Mayo Clinic proceedings, 1982, Volume: 57, Issue:8 Topics: Administration, Oral; Adult; Animals; Arrhythmias, Cardiac; Biological Availability; Calcium; Cardio	1982
Antiarrhythmic agents V--calcium blockers. Pharmacology & therapeutics, 1981, Volume: 15, Issue:3 Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers;	1981
[Post-infarction, myocardial ischemia: clinical importance and risk factor]. Archives des maladies du coeur et des vaisseaux, 1995, Volume: 88 Spec No 4 Topics: Arrhythmias, Cardiac; Humans; Myocardial Infarction; Myocardial Ischemia; Risk Factors; Verapamil	1995
What is the drug of choice for the acute termination of paroxysmal supraventricular tachycardia: verapamil, adenosine triphosphate, or adenosine? Pacing and clinical electrophysiology : PACE, 1993, Volume: 16, Issue:8 Topics: Adenosine; Adenosine Triphosphate; Adult; Arrhythmias, Cardiac; Child; Clinical Trials as Topic; Dru	1993
Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. The American journal of cardiology, 1996, Jun-20, Volume: 77, Issue:16 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Heart Failure; Humans; Myocardial	1996
Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine. The American journal of cardiology, 1996, Nov-07, Volume: 78, Issue:9A Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Cor	1996
Some similarities and differences between verapamil and the dihydropyridines. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1998, Volume: 16, Issue:1 Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Dihydropy	1998
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. American heart journal, 2002, Volume: 144, Issue:1 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial	2002
Cardiac arrhythmias - a short review. Scottish medical journal, 1976, Volume: 21, Issue:3 Topics: Adrenergic beta-Agonists; Arrhythmias, Cardiac; Digitalis Glycosides; Electric Countershock; Electro	1976
Limitations of present drug therapy of cardiac arrhythmias--a review. Postgraduate medical journal, 1977, Volume: 53 Suppl 1 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Com	1977
[Calcium antagonists in cardiology]. Bollettino della Societa italiana di cardiologia, 1978, Issue:1 Suppl Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Human	1978
Role of the slow current in cardiac electrophysiology. Circulation, 1975, Volume: 51, Issue:5 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Atrioventricular Node; Calcium; Cyclic AMP; Digita	1975
Clinical use of verapamil. Drugs, 1977, Volume: 13, Issue:3 Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction System; Hemodynamics; H	1977
Cardiac electrophysiologic alterations during myocardial ischemia. The American journal of physiology, 1977, Volume: 233, Issue:3 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Biological Transport; Coronary Disease; Dogs; Elec	1977
Papaverine as an antiarrhythmic agent. Angiology, 1977, Volume: 28, Issue:11 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Drug Evaluation, Preclinical	1977
Verapamil: a review of its pharmacological properties and therapeutic use. Drugs, 1978, Volume: 15, Issue:3 Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Corona	1978
Clinical aspects of Ca-blocking agents. Acta pharmacologica et toxicologica, 1978, Volume: 43 Suppl 1 Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium; Coronary Disease; Cricetinae; Humans; Hyper	1978
[Electrophysiological effects of calcium-antagonists and their use in arrhythmia]. Bollettino della Societa italiana di cardiologia, 1978, Issue:1 Suppl Topics: Arrhythmias, Cardiac; Atrioventricular Node; Calcium; Heart Rate; Humans; Nifedipine; Pyridines; Sin	1978
Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. American heart journal, 1975, Volume: 89, Issue:5 Topics: Action Potentials; Administration, Oral; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial	1975
[Verapamil--on the 30th anniversary of its clinical use]. Terapevticheskii arkhiv, 1992, Volume: 64, Issue:8 Topics: Arrhythmias, Cardiac; Arteriosclerosis; History, 20th Century; Humans; Hypertension; Myocardial Isch	1992
Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation, 1991, Volume: 84, Issue:5 Suppl Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Coronary Artery Bypass; Digoxin; Humans; Meta-Ana	1991
Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 6 Topics: Arrhythmias, Cardiac; Blood Pressure; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Female;	1991
[Mechanisms of interactions of anti-arrhythmia agents during their combined use]. Kardiologiia, 1991, Volume: 31, Issue:2 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digoxin; Drug Interactions; Drug Therapy,	1991
The treatment of ventricular rhythm disturbances. American heart journal, 1986, Volume: 111, Issue:6 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premat	1986
[Some advances in the study on heart alpha-adrenaline receptors]. Sheng li ke xue jin zhan [Progress in physiology], 1985, Volume: 16, Issue:4 Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Calcium; Ion Channels; Myocardium; Rece	1985
Verapamil and ventricular tachyarrhythmias. Pacing and clinical electrophysiology : PACE, 1987, Volume: 10, Issue:3 Pt 1 Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Coronary Disease; Electrophysiology; Heart Ventricle	1987
Clinical and electrophysiologic mechanisms of exercise-induced ventricular tachyarrhythmias. Pacing and clinical electrophysiology : PACE, 1988, Volume: 11, Issue:9 Topics: Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrophysiology; Humans; Myocardial Infarction;	1988
Management of supraventricular tachyarrhythmias. Comprehensive therapy, 1989, Volume: 15, Issue:4 Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Huma	1989
[Anti-arrhythmia therapy with Ca++-antagonists]. Orvosi hetilap, 1989, Jun-04, Volume: 130, Issue:23 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Humans; Tachycardia, Paroxysmal; Tachycardia, Suprav	1989
Use of calcium channel entry blockers in the treatment of cardiac arrhythmias. Circulation, 1989, Volume: 80, Issue:6 Suppl Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrioventricular Node; Calcium Channel Blockers; Dilti	1989
Digitalis toxicity. Annual review of medicine, 1985, Volume: 36 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Biological Availability; Carotid Sinus; Digitalis	1985
Selection of optimal drug therapy for the patient with angina pectoris. Mayo Clinic proceedings, 1985, Volume: 60, Issue:8 Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel	1985
Antiarrhythmic drug therapy. Recent advances and current status. Cardiology, 1985, Volume: 72, Issue:5-6 Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrh	1985
Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. Cardiology clinics, 1986, Volume: 4, Issue:2 Topics: Aged; Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Digox	1986
Antiarrhythmic drug therapy of ventricular arrhythmias. Current problems in cardiology, 1986, Volume: 11, Issue:4 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecaini	1986
Advances in calcium blocker therapy. American journal of surgery, 1986, Volume: 151, Issue:4 Topics: Arrhythmias, Cardiac; Arteriosclerosis; Asthma; Blood Platelet Disorders; Calcium; Calcium Channel B	1986
Mechanisms involved in reperfusion arrhythmias. European heart journal, 1986, Volume: 7 Suppl A Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Dil	1986
Verapamil in arrhythmia. British journal of clinical pharmacology, 1986, Volume: 21 Suppl 2 Topics: Arrhythmias, Cardiac; Humans; Verapamil	1986
Calcium channel blocking agents and the heart. British medical journal (Clinical research ed.), 1985, Oct-26, Volume: 291, Issue:6503 Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Vasospasm; Digoxin; Diltia	1985
[Heart rhythm disorders during pacemaker therapy]. Medizinische Klinik, 1973, Oct-05, Volume: 68, Issue:40 Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Electricity	1973
[Anti-arrhythmia agents]. Medizinische Klinik, 1974, May-03, Volume: 69, Issue:18 Topics: Action Potentials; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atri	1974
Comparative mechanisms of action of antiarrhythmic drugs. American heart journal, 1974, Volume: 87, Issue:3 Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzof	1974
[Treatment of arrhythmia in myocardial infarct]. Kardiologiia, 1968, Volume: 8, Issue:10 Topics: Amides; Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Cardiac Complexes, Premature; Cardiac G	1968
[Modern treatment of cardiac arrhythmias]. Munchener medizinische Wochenschrift (1950), 1971, Apr-16, Volume: 113, Issue:16 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bradycardia; Cell Membrane Permeability; Digitali	1971
Verapamil and the myocardium. Postgraduate medical journal, 1974, Volume: 50, Issue:585 Topics: Angina Pectoris; Arrhythmias, Cardiac; Biological Transport; Calcium; Coronary Vessels; Female; Hear	1974

Article	Year
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European heart journal, 2008, Volume: 29, Issue:10 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole	2008
Selection of an antiarrhythmic drug for a sudden-death-prevention trial. American heart journal, 1982, Volume: 103, Issue:4 Pt 2 Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac	1982
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Annals of internal medicine, 1980, Volume: 93, Issue:6 Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B	1980
Treatment of arrhythmias by blocking slow current. Annals of internal medicine, 1980, Volume: 93, Issue:6 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cardiovascular System; Clinical Tria	1980
Verapamil in the treatment of asystolic and pulseless idioventricular rhythm cardiopulmonary arrests: a preliminary report. Annals of emergency medicine, 1984, Volume: 13, Issue:4 Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Female; Heart Arrest; Hum	1984
[Calcium antagonists. Properties and current indications]. Recenti progressi in medicina, 1984, Volume: 75, Issue:4 Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diltiaze	1984
Abrupt withdrawal of verapamil in ischaemic heart disease. The Danish Study Group on Verapamil in Myocardial Infarction. European heart journal, 1984, Volume: 5, Issue:7 Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; F	1984
[Verapamil in the treatment and prevention of supraventricular disorders of cardiac rhythm]. Sovetskaia meditsina, 1984, Issue:7 Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Female	1984
Calcium antagonists: long-awaited new therapy for heart disease. JAMA, 1981, Feb-27, Volume: 245, Issue:8 Topics: Angina Pectoris; Arrhythmias, Cardiac; Benzazepines; Calcium; Cardiomyopathies; Clinical Trials as T	1981
Clinical uses of calcium ion antagonists in arrhythmias. Clinical and investigative medicine. Medecine clinique et experimentale, 1980, Volume: 3, Issue:1-2 Topics: Adult; Aged; Alprenolol; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Child, Preschool; Cl	1980
Hemodynamic effects in patients with cardiac arrhythmias. Clinical and investigative medicine. Medecine clinique et experimentale, 1980, Volume: 3, Issue:1-2 Topics: Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Digitalis Glycosides; Gallopamil; He	1980
Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta medica Scandinavica. Supplementum, 1981, Volume: 645 Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Electric Stimulation Therapy; H	1981
Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery. American heart journal, 1982, Volume: 104, Issue:4 Pt 1 Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Dose-Response Relationship, Drug; Do	1982
[Electrophysiological study of the effects of verapamil on normal and pathological sinus node function]. Annales de cardiologie et d'angeiologie, 1981, Volume: 30, Issue:6 Topics: Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Male; Middle Aged; Sinoatria	1981
Short- and long-term prognostic implications of in-hospital postinfarction arrhythmias. DAVIT II Study Group. Cardiology, 1995, Volume: 86, Issue:1 Topics: Aged; Arrhythmias, Cardiac; Humans; Multivariate Analysis; Myocardial Infarction; Prognosis; Verapam	1995
Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. The Danish Verapamil Infarction Trial II (DAVIT II). International journal of cardiology, 1995, Mar-03, Volume: 48, Issue:3 Topics: Aged; Arrhythmias, Cardiac; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; M	1995
Effect of verapamil on arrhythmias and heart rate during 16 months following an acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Cardiovascular drugs and therapy, 1994, Volume: 8, Issue:1 Topics: Aged; Arrhythmias, Cardiac; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Ma	1994
Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive care medicine, 1994, Volume: 20, Issue:1 Topics: Acute Disease; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Chi-Square Distribution; Electrocardio	1994
Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction. Clinical cardiology, 1993, Volume: 16, Issue:2 Topics: Aged; Arrhythmias, Cardiac; Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Fem	1993
The effect of magnesium versus verapamil on supraventricular arrhythmias. Clinical cardiology, 1993, Volume: 16, Issue:5 Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Heart Rate; Humans; Infusions, In	1993
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11 Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc	2000
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. American journal of hypertension, 2001, Volume: 14, Issue:7 Pt 1 Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood	2001
[Treatment of arrhythmias with verapamil]. Revista clinica espanola, 1977, Jun-15, Volume: 145, Issue:5 Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male;	1977
[Verapamil as an anti-arrhythmic agent. Experience with 86 consecutive cases treated by intravenous injection]. Ugeskrift for laeger, 1977, Nov-28, Volume: 139, Issue:48 Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials as Topic; Drug Evaluation; Heart Ar	1977
[Verapamil in the treatment of premature supraventricular and ventricular contractions. Clinical "standard" evaluation and evaluation using dynamic electrocardiography (Holter system). Double-blind study]. Arquivos brasileiros de cardiologia, 1978, Volume: 31 Suppl 1 Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiograph	1978
Verapamil in atrial fibrillation and atrial flutter. Clinical pharmacology and therapeutics, 1979, Volume: 26, Issue:5 Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Humans; Male; Middle Ag	1979
[Injectable verapamil in the anti-arrhythmia treatment]. La Clinica terapeutica, 1975, Nov-30, Volume: 75, Issue:4 Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Humans; Injections, Intravenous	1975
[Value of verapamil by oral administration in the treatment of chronic heart dysrhythmias]. Arquivos brasileiros de cardiologia, 1976, Volume: 29, Issue:2 Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Human	1976
Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. American heart journal, 1992, Volume: 123, Issue:6 Topics: Adenosine; Adult; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Humans; Male; Midd	1992
Treatment with verapamil during and after an acute myocardial infarction: a review based on the Danish Verapamil Infarction Trials I and II. The Danish Study Group on Verapamil in Myocardial Infarction. Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 6 Topics: Arrhythmias, Cardiac; Blood Pressure; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Female;	1991
Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group. Journal of cardiovascular pharmacology, 1991, Volume: 18 Suppl 6 Topics: Analysis of Variance; Arrhythmias, Cardiac; Coronary Disease; Female; Heart Rate; Humans; Male; Myoc	1991
[The prevalence of arrhythmias and repolarization changes in patients with mild or moderate essential hypertension undergoing an exercise test. Their variations with different antihypertensive treatments]. Anales de medicina interna (Madrid, Spain : 1984), 1990, Volume: 7, Issue:11 Topics: Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Echocardiogra	1990
Verapamil and ventricular tachyarrhythmias. Pacing and clinical electrophysiology : PACE, 1987, Volume: 10, Issue:3 Pt 1 Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Coronary Disease; Electrophysiology; Heart Ventricle	1987
Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting. The American journal of cardiology, 1989, May-01, Volume: 63, Issue:15 Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Artery Bypass; Digoxin; Drug Therapy, Combination; Femal	1989
[Comparative evaluation of the anti-arrhythmia effectiveness of mezotrin and izoptin]. Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR, 1986, Volume: 9, Issue:2 Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Diamines;	1986
Verapamil prophylaxis for postoperative atrial dysrhythmias: a prospective, randomized, double-blind study using drug level monitoring. The Annals of thoracic surgery, 1987, Volume: 43, Issue:5 Topics: Administration, Oral; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Clinical Trials as	1987
Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. The Annals of thoracic surgery, 1985, Volume: 39, Issue:4 Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Coronary Artery Bypass; Double	1985
[Isoptin treatment of patients with various forms of chronic coronary insufficiency]. Kardiologiia, 1970, Volume: 10, Issue:8 Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinica	1970
[The antiarrhythmic and coronary-dilating properties of verapamil in patients ith ischemic heart disease]. Arzneimittel-Forschung, 1970, Volume: 20 Topics: Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Arteriosclerosis; Bloo	1970
[Clinical study of verampamil in the treatment of patients with chronic coronary insufficiency]. Arzneimittel-Forschung, 1970, Volume: 20 Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arteriosclerosis; Corona	1970

verapamil and Arrhythmia

Research Excerpts

Research

Studies (574)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Number of Participants With Dose Limiting Toxicity

Diastolic Blood Pressure

Heart Rate

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Systolic Blood Pressure

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Change in Number of Absence Seizures From Week 8 (Baseline) to Week 12

Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit

Change in Number of Myoclonic Seizures From Week 8 (Baseline) to Week 12

Reviews

Trials

Other Studies